Ascentage Pharma Group International AAPG

Annual Quarterly

FY2024 · ended Dec 31, 2024 · Revenue $124.44M · Filed Apr 16, 2025

Ascentage Pharma Group International (AAPG) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $124.4 million and a net loss of $55.6 million. Free cash flow was -$18.6 million. As of Dec 31, 2024 it held $122.4 million in cash and investments and $339.5 million in total debt.

Revenue
$124.44M
Net income
$-55.58M
Operating cash flow
$-15.26M
Free cash flow
$-18.58M
EPS
$-0.18
Dividend per share
None
Shares outstanding
373.32M
+7.2% vs prior year
Net cash
$-217.10M
FY 2024
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AAPG (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Suzhou , Jiangsu
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
2023311

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2024
Dec 31, 2024
Revenue
$124.4M
Net income
-$55.6M
Diluted EPS
-$0.18
Operating cash flow
-$15.3M
Free cash flow
-$18.6M
Total liabilities
$321.1M
Stockholders' equity
$37.6M
Cash and investments
$122.4M
Total debt
$339.5M

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Oct 28, 2026 Oct 28, 2026
6-K Current report (foreign issuer) Oct 22, 2026 Oct 22, 2026
6-K Current report (foreign issuer) Oct 21, 2026 Oct 21, 2026
6-K Current report (foreign issuer) Oct 15, 2026 Oct 15, 2026
6-K Current report (foreign issuer) Sep 29, 2026 Sep 28, 2026
6-K Current report (foreign issuer) Sep 17, 2026 Sep 17, 2026

All 132 Ascentage Pharma Group International SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.